+14.4%
TFC vs MRNA
+511.3%
-496.9%
-20.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.1% | -2.2% | +2.3% | +0.1% |
| 7D | +2.4% | +5.5% | -3.1% | +2.5% |
| 30D | -1.3% | +158.7% | -160.0% | -0.5% |
| 3M | +6.1% | +182.1% | -176.1% | +6.3% |
| 6M | +7.3% | +151.8% | -144.5% | +8.0% |
| YTD | +8.2% | +393.6% | -385.4% | +4.6% |
| 1Y | +14.4% | +499.5% | -485.0% | +9.4% |
| All | +14.4% | +511.3% | -496.9% | +9.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling